Trial Profile
A Phase I/II Double-Blind, Dose Ranging, Vehicle Controlled, Randomized, Parallel Groups, Safety, Tolerability and Efficacy Study of CHRONSEAL® (5-amino-acid Deleted Recombinant Human Hepatocyte Growth Factor (KP-dHGF)), in Subjects With Venous Leg Ulcers
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Hepatocyte growth factor (Primary)
- Indications Leg ulcer
- Focus Adverse reactions
- Sponsors Kringle Pharma
- 13 May 2014 New trial record